202 related articles for article (PubMed ID: 35502272)
1. Comparison of
Dadgar H; Norouzbeigi N; Jokar N; Zareizadeh J; Gholamrezanezhad A; Ahmadzadehfar H; Abbaszadeh M; Assadi M
World J Nucl Med; 2022 Mar; 21(1):1-8. PubMed ID: 35502272
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases.
Iagaru A; Mittra E; Dick DW; Gambhir SS
Mol Imaging Biol; 2012 Apr; 14(2):252-9. PubMed ID: 21479710
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Intra-individual comparison of
Bénard F; Harsini S; Wilson D; Zukotynski K; Abikhzer G; Turcotte E; Cossette M; Metser U; Romsa J; Martin M; Mar C; Saad F; Soucy JP; Eigl BJ; Black P; Krauze A; Burrell S; Nichol A; Tardif JC
Lancet Oncol; 2022 Dec; 23(12):1499-1507. PubMed ID: 36343655
[TBL] [Abstract][Full Text] [Related]
5. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Bone Metastases between
Wang D; Yang Y; Zeng Z; Ye J; Guo C; Huang S; Guo X; Xiao J
Contrast Media Mol Imaging; 2022; 2022():5975338. PubMed ID: 35494210
[TBL] [Abstract][Full Text] [Related]
7. The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan.
Damle NA; Bal C; Bandopadhyaya GP; Kumar L; Kumar P; Malhotra A; Lata S
Jpn J Radiol; 2013 Apr; 31(4):262-9. PubMed ID: 23377765
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
9. Is (99m)Tc-MDP whole body bone scintigraphy adjuvant to (18)F-FDG-PET for the detection of skeletal metastases?
Sahin E; Zincirkeser S; Akcan AB; Elboga U
J BUON; 2014; 19(1):291-6. PubMed ID: 24659678
[TBL] [Abstract][Full Text] [Related]
10. (18)F-FDG positron emission tomography/computed tomography and (99m)Tc-MDP skeletal scintigraphy in a case of Erdheim-Chester disease.
Asabella AN; Cimmino A; Altini C; Notaristefano A; Rubini G
Hell J Nucl Med; 2011; 14(3):311-2. PubMed ID: 22087457
[TBL] [Abstract][Full Text] [Related]
11.
Langsteger W; Rezaee A; Pirich C; Beheshti M
Semin Nucl Med; 2016 Nov; 46(6):491-501. PubMed ID: 27825429
[No Abstract] [Full Text] [Related]
12. The role of 18F-NaF PET/CT in metastatic bone disease.
Araz M; Aras G; Küçük ÖN
J Bone Oncol; 2015 Sep; 4(3):92-7. PubMed ID: 26587375
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 18F fluoride PET/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma.
Chakraborty D; Bhattacharya A; Mete UK; Mittal BR
Clin Nucl Med; 2013 Aug; 38(8):616-21. PubMed ID: 23603596
[TBL] [Abstract][Full Text] [Related]
14. Quantitative
Coskun N; Cagdas B; Yildirim N
Hell J Nucl Med; 2022; 25(2):132-137. PubMed ID: 35913859
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
16. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.
Iagaru A; Young P; Mittra E; Dick DW; Herfkens R; Gambhir SS
Clin Nucl Med; 2013 Jul; 38(7):e290-6. PubMed ID: 23455520
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients.
Yen RF; Chen CY; Cheng MF; Wu YW; Shiau YC; Wu K; Hong RL; Yu CJ; Wang KL; Yang RS
Nucl Med Commun; 2010 Jul; 31(7):637-45. PubMed ID: 20389259
[TBL] [Abstract][Full Text] [Related]
18. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
Ak I; Sivrikoz MC; Entok E; Vardareli E
Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
[TBL] [Abstract][Full Text] [Related]
19. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the diagnostic value of 18F-NaF PET/CT and
Fan Z; Wang T; Zou L; Liu D
Transl Cancer Res; 2023 Nov; 12(11):3166-3178. PubMed ID: 38130318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]